Svetlana Nikic, founder of Precision Oncology Consulting, is convening the inaugural European Precision Oncology Circle alongside the European Society for Medical Oncology (ESMO) conference, according to a recent professional announcement. Scheduled for Oct. 23, the gathering brings together senior leaders from molecular diagnostics, biopharma, clinical practice, pathology, and investment for an informal evening designed around professional networking and cross-sector collaboration.
Building Cross-Sector Connections in European Oncology
The Madrid-based networking event breaks away from traditional conference formats by omitting panels and formal presentations entirely. According to Nikic’s announcement, the objective is simply to place key stakeholders in the same room to foster organic conversations. Attendees work at the intersection of precision oncology, diagnostics, patient access, and investment.
Did you know? Svetlana Nikic brings more than 18 years of international experience across the global genomics and life sciences industry, having previously held roles at organizations like Roche Diagnostics and Illumina.
Translating Genomic Technologies into Clinical Practice
Precision Oncology Consulting advises diagnostics companies, biotechnology organizations, and healthcare stakeholders on evidence generation and market access pathways. According to background details from the firm, Nikic’s work centers on comprehensive genomic profiling, whole-genome sequencing, liquid biopsy, and minimal residual disease testing. Initiatives like the European Precision Oncology Circle aim to support the responsible adoption of these diagnostic innovations across European healthcare systems.
Frequently Asked Questions
When and where is the European Precision Oncology Circle taking place?
The first gathering is scheduled for Oct. 23, coinciding with the ESMO conference in Madrid, according to the organizer’s announcement.
Who is eligible to attend the gathering?
The event is designed for a small, curated group of senior leaders working at the intersection of precision oncology, molecular diagnostics, biopharma, clinical practice, pathology, and investment, as stated by Precision Oncology Consulting.
Are there formal presentations scheduled?
Worth a look